Combination therapy for chronic hepatitis B: Ready for prime time?

Journal of Hepatology

Volumn 48, Issue 5, 2008, Pages 687-691

  Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; TENOFOVIR;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; EDITORIAL; HEPATITIS B; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; SEROCONVERSION; SEROLOGY; TREATMENT OUTCOME; VIRUS LOAD;

CLINICAL TRIALS AS TOPIC; DNA, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS;

EID: 40949103032     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.02.006     Document Type: Editorial

References (33)

1. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
2. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
3. Niederau C., Heintges T., Lenge S., Goldmann G., Niederau C.M., Mohr L., et al. Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
4. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
5. Di Marco V., Marzano A., Lampertico P., Andreone P., Santantonio T., Almasio P.L., et al. Clinical outcome of HBeAg-negative chronic hepatitis in relation to virological response to lamivudine. Ann Int Med 40 (2004) 883-891
6. Lai M., Hyatt B.J., Nasser I., Curry M., and Afdhal N.H. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 47 (2007) 760-767
7. Yang L.M., Xu K.C., Zhao Y.L., Wu Z.R., Chen T.F., Qin Z.Y., et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminases. Chin J Dig Dis 4 (2002) 150-153
8. Yuen M.F., Yuan H.J., Wong D.K.H., Yuen J.C., Wong W.M., Chan A.O., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
9. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
10. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003;38:S3-S25.
11. Liaw Y.F., Leung N., Guan R., Lau G.K., Merican I., McCaughan G., et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25 (2005) 472-489
12. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
13. Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD, Kotzev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. American Association for the Study of Liver Diseases, 58th annual meeting, 2007: late breaking abstract 2. Hepatology 2007;46:290A.
14. Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103. American Association for the Study of Liver Diseases, 58th annual meeting, 2007: late breaking abstract 6. Hepatology 2007;46:861A.
15. Yoo B.C., Kim J.H., Kim T.H., Koh K.C., Um S.H., Kim Y.S., et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off therapy viral suppression. Hepatology 46 (2007) 1041-1048
16. Gish R, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg-positive chronic hepatitis B infection: observations from antiviral-naïve patients treated with entecavir or lamivudine. 57th annual meeting of the American Association for the Study of Liver Diseases, 2006. Hepatology 2006;44:558A.
17. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
18. Han S., Chang T.T., Chao Y.C., Yoon S.-K., Gish R.G., Cheinquer H., et al. Four-year entecavir treatment in nucleoside-naive HbeAg+ patients: results from studies ETV-022 and -901. Hepatology 46 (2007) 654A
19. Sherman M., Rizzetto M., Lai C.L., Liaw Y.-F., Gadano A., Jacobson I.M., et al. Long-term follow-up of entecavir treated protocol-defined nonresponders in rollover study ETV-901. Hepatology 46 (2007) 682A
20. Kieffer T.L., Sarrazin C., Miller J.S., Welker M.W., Forestier N., Reesink H.W., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46 (2007) 631-639
21. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
22. Lampertico P., Viganò M., Manenti E., Iavarone M., Sablon E., and Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
23. Sung J.J.Y., Lai J.Y., Zeuzem S., Chow W.C., Heathcote E.J., Perrillo R.P., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48 (2008) 728-735
24. Hui C.K., Zhang H.Y., Bowden S., Locarnini S., Luk J.M., Leung K.-W., et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine versus adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 48 (2008) 714-720
25. Sung J.J.Y., Lau J.Y., Zeuzem S., Chow W.C., Heathcote E., Perrillo R., et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine and adefovir for treatment-naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 38 (2003) 25-26
26. Lim S.G., Ng T.M., Kung N., Krastev Z., Volfova M., Husa P., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 166 (2006) 49-56
27. Van Bommel F., De Man R.A., Erhardt A., Huppe D., Stein K., Buggish P., et al. First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection. Hepatology 46 (2007) 270A
28. Benhamou Y., Fleury H., Trimoulet P., Pellegrin I., Urbinelli R., Katlama C., et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 (2006) 548-555
29. Zeuzem S., Buti M., Gane E.J., Liaw Y.-F., Di Bisceglie A.M., Heathcote E.J., et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE Study). Hepatology 46 (2007) 681A
30. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
31. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
32. http://clinicaltrials.gov/.
33. Keeffe E.B., Zeuzem S., Koff R.S., Dieterich D.T., Esteban-Mur R., Gane E.J., et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5 (2007) 890-897